(Q45151761)

10 December 2017

0 references

Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis (English)

1 reference

primary sclerosing cholangitis

10 December 2017

main subject

ascending cholangitis

0 references

1 reference

1 reference

C K Triantos

1

1 reference

10 December 2017

N M Koukias

series ordinal

2

1 reference

10 December 2017

V N Nikolopoulou

series ordinal

3

1 reference

10 December 2017

A K Burroughs

series ordinal

4

1 reference

10 December 2017

language of work or name

English

0 references

publication date

22 August 2011

1 reference

Alimentary Pharmacology & Therapeutics

10 December 2017

published in

1 reference

10 December 2017

volume

34

1 reference

10 December 2017

issue

8

1 reference

10 December 2017

page(s)

901-910

1 reference

Primary sclerosing cholangitis: summary of a workshop

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

An assessment of clinically useful measures of the consequences of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

An update on primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Current treatments of primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Endoscopy in the management of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Follow-up after liver transplantation for primary sclerosing cholangitis: effects on survival, quality of life, and colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Use of ursodeoxycholic acid in patients with liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04822.X

10.1111/J.1365-2036.2011.04822.X

21 January 2018

Identifiers

DOI

1 reference

10 December 2017

1 reference